Literature DB >> 7025662

Control of glomerular filtration rate by circulating angiotensin II.

J E Hall, T G Coleman, A C Guyton, P R Kastner, J P Granger.   

Abstract

Previous studies from our laboratory have provided evidence that the renin-angiotensin system plays an important role in controlling glomerular filtration rate (GFR) through an efferent arteriolar vasoconstrictor mechanism; however, the relative importance of circulating versus intrarenally formed angiotensin II (ANG II) in this control has not been determined. In the present study, the role of circulating ANG II in regulating GFR during reduced renal artery pressure (RAP) was examined in sodium-depleted dogs. After 90 min of infusion of the angiotensin-converting enzyme inhibitor SQ 14225, which presumably inhibited formation of both circulating and intrarenal ANG II, reduction of RAP to 81 +/- 2 mmHg resulted in marked decreases in GFR, filtration fraction (FF), and calculated efferent arteriolar resistance (RE), whereas renal blood flow (RBF) was maintained approximately 40% above initial control levels determined before SQ 14225 infusion. Replacement of circulating ANG II during SQ 14225 infusion, by intravenous infusion of ANG II at rates that decreased RBF to control levels, increased GFR, FF, and RE to levels not significantly different from control while RAP was maintained constant by aortic constriction. These observations suggest that circulating ANG II plays an important role in regulating RE and GFR during reductions in RAP. The importance of intrarenally formed ANG II in controlling GFR remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7025662     DOI: 10.1152/ajpregu.1981.241.3.R190

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  17 in total

1.  Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats.

Authors:  R Folgert G Haverdings; Marijke Haas; Gerjan Navis; Anne-Miek Van Loenen-Weemaes; Dirk K F Meijer; Dick De Zeeuw; Frits Moolenaar
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

Review 2.  Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease.

Authors:  Ravi Nistala; Yongzhong Wei; James R Sowers; Adam Whaley-Connell
Journal:  Transl Res       Date:  2009-01-23       Impact factor: 7.012

3.  Postischemic diagnostic localization of tubular lesions.

Authors:  G Kehrer; H J Bretschneider
Journal:  Klin Wochenschr       Date:  1990-02-15

Review 4.  Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure.

Authors:  Branko Braam; William A Cupples; Jaap A Joles; Carlo Gaillard
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

5.  Frusemide, ACE inhibition, renal dopamine and prostaglandins: acute interactions in normal man.

Authors:  T M MacDonald; K Craig; M L Watson
Journal:  Br J Clin Pharmacol       Date:  1989-12       Impact factor: 4.335

Review 6.  Redox control of renal function and hypertension.

Authors:  Ravi Nistala; Adam Whaley-Connell; James R Sowers
Journal:  Antioxid Redox Signal       Date:  2008-12       Impact factor: 8.401

7.  Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease.

Authors:  A J Apperloo; D de Zeeuw; H E Sluiter; P E de Jong
Journal:  BMJ       Date:  1991-10-05

8.  Urinary kallikrein excretion during inhibition of endogenous angiotensin II in the pig.

Authors:  B R Binder; M Maier; H Rana; M Starlinger; Z Zhegu
Journal:  Br J Pharmacol       Date:  1986-07       Impact factor: 8.739

9.  Immediate and prolonged hemodynamic effects of TA-3090 on spontaneously hypertensive (SHR) and normal Wistar-Kyoto (WKY) rats.

Authors:  T Isshiki; B L Pegram; E D Frohlich
Journal:  Cardiovasc Drugs Ther       Date:  1988-11       Impact factor: 3.727

10.  Diltiazem maintains renal vasodilation without hyperfiltration in hypertension: studies in essential hypertension man and the spontaneously hypertensive rat.

Authors:  T Isshiki; C Amodeo; F H Messerli; B L Pegram; E D Frohlich
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.